Your browser doesn't support javascript.
loading
Association Study between Polymorphisms in DNA Methylation-Related Genes and Testicular Germ Cell Tumor Risk.
Grasso, Chiara; Popovic, Maja; Isaevska, Elena; Lazzarato, Fulvio; Fiano, Valentina; Zugna, Daniela; Pluta, John; Weathers, Benita; D'Andrea, Kurt; Almstrup, Kristian; Anson-Cartwright, Lynn; Bishop, D Timothy; Chanock, Stephen J; Chen, Chu; Cortessis, Victoria K; Dalgaard, Marlene D; Daneshmand, Siamak; Ferlin, Alberto; Foresta, Carlo; Frone, Megan N; Gamulin, Marija; Gietema, Jourik A; Greene, Mark H; Grotmol, Tom; Hamilton, Robert J; Haugen, Trine B; Hauser, Russ; Karlsson, Robert; Kiemeney, Lambertus A; Lessel, Davor; Lista, Patrizia; Lothe, Ragnhild A; Loveday, Chey; Meijer, Coby; Nead, Kevin T; Nsengimana, Jérémie; Skotheim, Rolf I; Turnbull, Clare; Vaughn, David J; Wiklund, Fredrik; Zheng, Tongzhang; Zitella, Andrea; Schwartz, Stephen M; McGlynn, Katherine A; Kanetsky, Peter A; Nathanson, Katherine L; Richiardi, Lorenzo.
Afiliação
  • Grasso C; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Popovic M; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Isaevska E; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Lazzarato F; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Fiano V; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Zugna D; Cancer Epidemiology Unit, Department of Medical Sciences, University of Turin and CPO Piedmont, Turin, Italy.
  • Pluta J; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Weathers B; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • D'Andrea K; Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Almstrup K; Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Anson-Cartwright L; Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Bishop DT; Department of Surgery (Urology), University of Toronto and The Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Chanock SJ; Department of Haematology and Immunology, Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, United Kingdom.
  • Chen C; Division of Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Cortessis VK; Program in Epidemiology, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Dalgaard MD; Department of Epidemiology, University of Washington, Seattle, Washington.
  • Daneshmand S; Department of Population and Public Health Sciences, and Obstetrics and Gynecology, Keck School of Medicine at the University of Southern California, Los Angeles, California.
  • Ferlin A; Department of Health Technology, Technical University of Denmark, Lyngby, Denmark.
  • Foresta C; Department of Urology, Keck School of Medicine at the University of Southern California, Los Angeles, California.
  • Frone MN; Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padova, Italy.
  • Gamulin M; Unit of Andrology and Reproductive Medicine, Department of Medicine, University of Padova, Padova, Italy.
  • Gietema JA; Division of Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Greene MH; Department of Oncology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia.
  • Grotmol T; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Hamilton RJ; Division of Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
  • Haugen TB; Department of Research, Cancer Registry of Norway, Oslo, Norway.
  • Hauser R; Department of Surgery (Urology), University of Toronto and The Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Karlsson R; Faculty of Health Sciences, OsloMet - Oslo Metropolitan University, Oslo, Norway.
  • Kiemeney LA; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts.
  • Lessel D; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Lista P; Radboud University Medical Center, Nijmegen, the Netherlands.
  • Lothe RA; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Loveday C; Division of Medical Oncology, AOU "Città della Salute e della Scienza di Torino", Turin, Italy.
  • Meijer C; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  • Nead KT; Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
  • Nsengimana J; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Skotheim RI; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Turnbull C; Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Vaughn DJ; Biostatistics Research Group, Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom.
  • Wiklund F; Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  • Zheng T; Department of Informatics, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
  • Zitella A; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Schwartz SM; Royal Marsden NHS Foundation Hospital, London, United Kingdom.
  • McGlynn KA; Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Kanetsky PA; Abramson Cancer Center, Perelman School of Medicine, Philadelphia, Pennsylvania.
  • Nathanson KL; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Richiardi L; Department of Epidemiology, Brown School of Public Health, Brown University, Providence, Rhode Island.
Cancer Epidemiol Biomarkers Prev ; 31(9): 1769-1779, 2022 09 02.
Article em En | MEDLINE | ID: mdl-35700037
BACKGROUND: Testicular germ cell tumors (TGCT), histologically classified as seminomas and nonseminomas, are believed to arise from primordial gonocytes, with the maturation process blocked when they are subjected to DNA methylation reprogramming. SNPs in DNA methylation machinery and folate-dependent one-carbon metabolism genes have been postulated to influence the proper establishment of DNA methylation. METHODS: In this pathway-focused investigation, we evaluated the association between 273 selected tag SNPs from 28 DNA methylation-related genes and TGCT risk. We carried out association analysis at individual SNP and gene-based level using summary statistics from the Genome Wide Association Study meta-analysis recently conducted by the international Testicular Cancer Consortium on 10,156 TGCT cases and 179,683 controls. RESULTS: In individual SNP analyses, seven SNPs, four mapping within MTHFR, were associated with TGCT risk after correction for multiple testing (q ≤ 0.05). Queries of public databases showed that three of these SNPs were associated with MTHFR changes in enzymatic activity (rs1801133) or expression level in testis tissue (rs12121543, rs1476413). Gene-based analyses revealed MTHFR (q = 8.4 × 10-4), methyl-CpG-binding protein 2 (MECP2; q = 2 × 10-3), and ZBTB4 (q = 0.03) as the top TGCT-associated genes. Stratifying by tumor histology, four MTHFR SNPs were associated with seminoma. In gene-based analysis MTHFR was associated with risk of seminoma (q = 2.8 × 10-4), but not with nonseminomatous tumors (q = 0.22). CONCLUSIONS: Genetic variants within MTHFR, potentially having an impact on the DNA methylation pattern, are associated with TGCT risk. IMPACT: This finding suggests that TGCT pathogenesis could be associated with the folate cycle status, and this relation could be partly due to hereditary factors.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Seminoma / Neoplasias Embrionárias de Células Germinativas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Testiculares / Seminoma / Neoplasias Embrionárias de Células Germinativas Idioma: En Ano de publicação: 2022 Tipo de documento: Article